|
1
|
Klöppel G: Neuroendocrine neoplasms:
Dichotomy, origin and classifications. Visc Med. 33:324–330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oberg K, Modlin IM, de Herder W, Pavel M,
Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg
J, et al: Consensus on biomarkers for neuroendocrine tumour
disease. Lancet Oncol. 16:e435–e446. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cheung VTF and Khan MS: A guide to midgut
neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline
Gastroenterol. 6:264–269. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pedraza-Arévalo S, Gahete MD, Alors-Pérez
E, Luque RM and Castaño JP: Multilayered heterogeneity as an
intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab
Disord. 19:179–192. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Modlin IM, Gustafsson BI, Moss SF, Pavel
M, Tsolakis AV and Kidd M: Chromogranin A-biological function and
clinical utility in neuro endocrine tumor disease. Ann Surg Oncol.
17:2427–2443. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zatelli MC, Grossrubatscher EM, Guadagno
E, Sciammarella C, Faggiano A and Colao A: Circulating tumor cells
and mirnas as prognostic markers in neuroendocrine neoplasms.
Endocr Relat Cancer. 24:R223–R237. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sechidis K, Papangelou K, Metcalfe PD,
Svensson D, Weatherall J and Brown G: Distinguishing prognostic and
predictive biomarkers: An information theoretic approach.
Bioinformatics. 34:3365–3376. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lloyd RV, Osamura RY, Klöppel G and Rosai
J (eds): WHO Classification of Tumours of Endocrine Organs. 4th
edition, Volume 10. Lloyd RV, Osamura RY, IARC, 2017.
|
|
9
|
Rindi G, Klimstra DS, Abedi-Ardekani B,
Brambilla E, Asa LS, Bosman TF, Busam JK, Dietel M,
Fernandez-Cuesta L, Sasano H, et al: A common classification
framework for neuroendocrine neoplasms: An International Agency for
Research on Cancer (IARC) and World Health Organization (WHO)
expert consensus proposal. Mod Pathol. 31:1770–1786.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rindi G and Inzani F: Neuroendocrine
neoplasm update: Toward universal nomenclature. Endocr Relat
Cancer. 27:R211–R218. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Herrera-Martínez AD, Hofland LJ, Gálvez
Moreno MA, Castaño JP, de Herder WW and Feelders RA: Neuroendocrine
neoplasms: Current and potential diagnostic, predictive and
prognostic markers. Endocr Relat Cancer. 26:R157–R179.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rindi G, Klöpper G, Alhman H, Caplin M,
Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M,
Komminoth P, et al: TNM staging of foregut (neuro)endocrine tumors:
A consensus proposal including a grading system. Virchows Arch.
449:395–401. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rindi G, Klöpper G, Couvelard A, Komminoth
P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A,
et al: TNM staging of midgut and hindgut (neuro) endocrine tumors:
A consensus proposal including a grading system. Virchows Arch.
451:757–762. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cho JH, Ryu JK, Song SY, Hwang JH, Lee DK,
Woo SM, Joo YE, Jeong S, Lee SO, Park BK, et al: Prognostic
validity of the American joint committee on cancer and the European
neuroendocrine tumors staging classifications for pancreatic
neuroendocrine tumors: A retrospective nationwide multicenter study
in South Korea. Pancreas. 45:941–946. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Strosberg JR, Cheema A, Weber J, Han G,
Coppola D and Kvols LK: Prognostic validity of a novel American
Joint Committee on Cancer Staging Classification for pancreatic
neuroendocrine tumors. J Clin Oncol. 29:3044–3049. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rindi G, Falconi M, Klersy C, Albarello L,
Boninsegna L, Buchler WM, Capella C, Caplin M, Couvelard A,
Doglioni C, et al: TNM staging of neoplasms of the endocrine
pancreas: Results from a large international cohort study. J Natl
Cancer Inst. 104:764–777. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gustafsson BI, Kidd M, Chan A,
Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine
tumors. Cancer. 113:5–21. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Flemming JB, Vauthey IN, Rashid A and
Evans DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Garcia-Carbonero R, Capdevila J,
Crespo-Herrero G, Díaz Pérez JA, Martínez Del Prado MP, Alonso
Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez
A, Llanos-Muñoz M, et al: Incidence, patterns of care and
prognostic factors for outcome of gastroenteropancreatic
neuroendocrine tumors (GEP-NETs): Results from the National cancer
registry of Spain (RGETNE). Ann Oncol. 21:1794–1803.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ruzzenente A, Bagante F, Bertuzzo F,
Aldrighetti L, Ercolani G, Giuliante F, Ferrero A, Torzilli G,
Grazi GL, Ratti F, et al: A novel nomogram to predict the prognosis
of patients undergoing liver resection for neuroendocrine liver
metastasis: An analysis of the Italian neuroendocrine liver
metastasis database. J Gastrointest Surg. 21:41–48. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie
JW, Wang JB, Chen QY, Lin M, Tu RH and Huang CM: A novel predictive
model based on preoperative blood neutrophilto-lymphocyte ratio for
survival prognosis in patients with gastric neuroendocrine
neoplasms. Oncotarget. 7:42045–42058. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Villani V, Mahadevan KK, Ligorio M,
Fernández-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M,
Ferrone S, Warshaw AL, et al: Phosphorylated histone H3 (PHH3) is a
superior proliferation marker for prognosis of pancreatic
neuroendocrine tumors. Ann Surg Oncol. 23 (Suppl 5):S609–S617.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Modlin IM, Moss SF, Chung DC, Jensen RT
and Snyderwine E: Priorities for improving the management of
gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst.
100:1282–1289. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Turner GB, Johnston BT, McCance DR,
McGinty A, Watson RGP, Patterson CC and Ardill JE: Circulating
markers of prognosis and response to treatment in patients with
midgut carcinoid tumours. Gut. 55:1586–1591. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Modlin IM, Oberg K, Taylor A, Drozdov I,
Bodei L and Kidd M: Neuroendocrine tumor biomarkers: Current status
and perspectives. Neuroendocrinology. 100:265–277. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kulke MH, Siu LL, Tepper JE, Fisher G,
Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday
TJ, et al: Future directions in the treatment of neuroendocrine
tumors: Consensus report of the National cancer institute
neuroendocrine tumor clinical trials planning meeting. J Clin
Oncol. 29:934–943. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ambrosini V, Kunikowska J, Baudin E, Bodei
L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C,
Falconi M, et al: Consensus on molecular imaging and theranostics
in neuroendocrine neoplasms. Eur J Cancer. 146:56–73.
2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Majala S, Seppänen H, Kemppainen J,
Sundström J, Shalin-Jäntti C, Gullichsen R, Schildt J, Mustonen H,
Vesterinen T, Arola J and Kauhanen S: Prediction of the
aggressiveness of non-functional pancreatic neuroendocrine tumors
based on the dual-tracer PET/CT. EJNMMI Res. 9(116)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bodei L, Sundin A, Kidd M, Prasad V and
Modlin IM: The status of neuroendocrine tumor imaging: From
darkness to light? Neuroendocrinology. 101:1–17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Righi L, Volante M, Tavaglione V, Billè A,
Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G and Pappotti M:
Somatostatin receptor tissue distribution in lung neuroendocrine
tumours: A clinicopathologic and immunohistochemical study of 218
‘clinically aggressive’ cases. Ann Oncol. 21:548–555.
2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Reubi JC, Waser B, Cescato R, Gloor B,
Stettler C and Christ E: Internalized somatostatin receptor subtype
2 in neuroendocrine tumors of octreotide-treated patients. J Clin
Endocrinol Metab. 95:2343–2350. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lamarca A, Crona J, Ronot M, Opalinska M,
Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO,
Borg P, et al: Value of tumor growth rate (TGR) as an early
biomarker predictor of patients' outcome in neuroendocrine tumors
(NET)-The GREPONET Study. Oncologist. 24:e1082–e1090.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lamarca A, Ronot M, Moalla S, Crona J,
Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L,
Bezerra ROF, et al: Tumor growth rate as a validated early
radiological biomarker able to reflect treatment-induced changes in
neuroendocrine tumors: The GREPONET-2 study. Clin Cancer Res.
25:6692–6699. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
De Rubis G, Rajeev Krishnan S and Bebawy
M: Liquid biopsies in cancer diagnosis, monitoring, and prognosis.
Trends Pharmacol Sci. 40:172–186. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Malczewska A, Kos-Kudła B, Kidd M, Drozdov
I, Bodei L, Matar S, Oberg K and Modlin IM: The clinical
applications of a multigene liquid biopsy (NETest) in
neuroendocrine tumors. Adv Med Sci. 65:18–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nehar D, Lombard-Bohas C, Olivieri S,
Claustrat B, Chayvialle JA, Penes MC, Sassolas G and Borson-Chazot
F: Interest of chromogranin a for diagnosis and follow-up of
endocrine tumours. Clin Endocrinol (Oxf). 60:644–652.
2004.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Baekdal J, Krogh J, Klose M, Holmager P,
Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF,
et al: Limited diagnostic utility of chromogranin A measurements in
workup of neuroendocrine tumors. Diagnostics (Basel).
10(881)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gkolfinopoulos S, Tsapakidis K,
Papadimitriou K, Papamichael D and Kountourakis P: Chromogranin A
as a valid marker in oncology: Clinical application or false hopes?
World J Methodol. 7:9–15. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Malczewska A, Kidd M, Matar S, Kos-Kudła
B, Bodei L, Oberg K and Modlin IM: An assessment of circulating
chromogranin a as a biomarker of bronchopulmonary neuroendocrine
Neoplasia: A systematic review and meta-analysis.
Neuroendocrinology. 110:198–216. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zatelli MC, Torta M, Leon A, Ambrosio MR,
Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L and
degli Uberti EC: Italian CromaNet Working Group. Chromogranin A as
a marker of neuroendocrine neoplasia: An Italian multicenter study.
Endocr Relat Cancer. 14:473–482. 2007.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Campana D, Nori F, Piscitelli L,
Morselli-Labate AM, Pezzilli R, Corinaldesi R and Tomassetti P:
Chromogranin A: Is it a useful marker of neuroendocrine tumors? J
Clin Oncol. 25:1967–1973. 2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Stridsberg M, Oberg K, Li Q, Engstrom U
and Lundqvist G: Measurements of chromogranin A, chromogranin B
(secretogranin I), chromogranin C (secretogranin II) and
pancreastatin in plasma and urine from patients with carcinoid
tumours and endocrine pancreatic tumours. J Endocrinol. 144:49–59.
1995.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Chan DL, Clarke SJ, Diakos CI, Roach PJ,
Bailey DL, Singh S and Pavlakis N: Prognostic and predictive
biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol.
113:268–282. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Baudin E, Bidart JM, Bachelot A, Ducreux
M, Elias D, Rufflé P and Schlumberger M: Impact of chromogranin A
measurement in the work-up of neuroendocrine tumors. Ann Oncol 12
Suppl. 2:S79–S82. 2001.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Nölting S, Kuttner A, Lauseker M, Vogeser
M, Haug A, Hermann KA, Hoffmann JN, Spitzweg C, Göke B and
Auernhammer CJ: Chromogranin a as serum marker for
gastroenteropancreatic neuroendocrine tumors: A single center
experience and literature review. Cancers (Basel). 4:141–155.
2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Mashige F, Matsushimal Y, Kanazawal H,
Sakuma I, Takai N, Besshof F and Ohkubo A: Acidic catecholamine
metabolites and 5-hydroxyindoleacetic acid in urine: The influence
of diet. Ann Clin Biochem. 33:43–49. 1996.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Feldman JM: Urinary serotonin in the
diagnosis of carcinoid tumors. Clin Chem. 32:840–844.
1986.PubMed/NCBI
|
|
52
|
Sjöblom SM: Clinical presentation and
prognosis of gastrointestinal carcinoid tumours. Scand J
Gastroenterol. 23:779–787. 1988.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Bhattacharyya S, Raja SG, Toumpanakis C,
Caplin ME, Dreyfus GD and Davar J: Outcomes, risks and
complications of cardiac surgery for carcinoid heart disease. Eur J
Cardiothorac Surg. 40:168–172. 2011.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Niederle B, Pape UF, Costa F, Gross D,
Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C,
et al: ENETS consensus guidelines update for neuroendocrine
neoplasms of the jejunum and ileum. Neuroendocrinology.
103:125–138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Korse CM, Taal BG, de Groot CA, Bakker RH
and Bonfrer JM: Chromogranin-A and N-terminal pro-brain natriuretic
peptide: An excellent pair of biomarkers for diagnostics in
patients with neuroendocrine tumor. J Clin Oncol. 27:4293–4299.
2009.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Modlin IM, Bodei L and Kidd M:
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts
and algorithms. Best Pract Res Clin Endocrinol Metab. 30:59–77.
2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Bhattacharyya S, Toumpanakis C, Caplin ME
and Davar J: Usefulness of N-terminal pro-brain natriuretic peptide
as a biomarker of the presence of carcinoid heart disease. Am J
Cardiol. 102:938–942. 2008.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Isgrò MA, Bottoni P and Scatena R:
Neuron-specifi c enolase as a biomarker: Biochemical and clinical
aspects. Adv Exp Med Biol. 867:125–143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Baudin E, Gigliotti A, Ducreux M, Ropers
J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié
P and Schlumberger M: Neuron-specific enolase and chromogranin A as
markers of neuroendocrine tumours. Br J Cancer. 78:1102–1107.
1998.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Walter T, Chardon L, Chopin-Laly X,
Raverot V, Caffin AG, Chayvialle JA, Scoazec JY and Lombard-Bohas
C: Is the combination of chromogranin A and pancreatic polypeptide
serum determinations of interest in the diagnosis and follow-up of
gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer.
48:1766–1773. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Laskaratos FM, Rombouts K, Caplin M,
Toumpanakis C, Thirlwell C and Mandair D: Neuroendocrine tumors and
fibrosis: An unsolved mystery? Cancer. 123:4770–4790.
2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Behnes M, Brueckmann M, Lang S, Weiß C,
Ahmad-Nejad P, Neumaier M, Borggrefe M and Hoffmann U: Connective
tissue growth factor (CTGF/CCN2): Diagnostic and prognostic value
in acute heart failure. Clin Res Cardiol. 103:107–116.
2014.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Cunningham JL, Tsolakis AV, Jacobson A and
Janson ET: Connective tissue growth factor expression in endocrine
tumors is associated with high stromal expression of alpha-smooth
muscle actin. Eur J Endocrinol. 163:691–697. 2010.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Kidd M, Modlin I, Shapiro M, Camp R, Mane
S, Usinger W and Murren J: CTGF, intestinal stellate cells and
carcinoid fibrogenesis. World J Gastroenterol. 13:5208–5216.
2007.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Bellizzi AM: Immunohistochemistry in the
diagnosis and classification of neuroendocrine neoplasms: What can
brown do for you? Hum Pathol. 96:8–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
McCall CM, Shi C, Cornish TC, Klimstra DS,
Tang LH, Basturk O, Mun LJ, Ellison TA, Wolfgang CL, Choti MA, et
al: Grading of well-differentiated pancreatic neuroendocrine tumors
is improved by the inclusion of both ki67 Proliferative index and
mitotic rate. Am J Surg Pathol. 37:1671–1677. 2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Bellizzi AM: Pathologic considerations in
gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am.
29:185–208. 2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Coriat R: Aggressive
gastro-entero-pancreatic neoplasms. Ann Endocrinol (Paris).
80:185–186. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Pape UF, Jann H, Müller-Nordhorn J,
Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G and
Wiedenmann B: Prognostic relevance of a novel TNM classification
system for upper gastroenteropancreatic neuroendocrine tumors.
Cancer. 113:256–265. 2008.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Strosberg J, Nasir A, Coppola D, Wick M
and Kvols L: Correlation between grade and prognosis in metastatic
gastroenteropancreatic neuroendocrine tumors. Hum Pathol.
40:1262–1268. 2009.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Lopez-Aguiar AG, Ethun CG, Postlewait LM,
Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Sarmiento JM,
Kooby DA, Staley CA, et al: Redefining the Ki-67 index
stratification for low-grade pancreatic neuroendocrine tumors:
Improving its prognostic value for recurrence of disease. Ann Surg
Oncol. 25:290–298. 2018.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zen Y and Heaton N: Elevated Ki-67
labeling index in ‘synchronous liver metastases’ of well
differentiated enteropancreatic neuroendocrine tumor. Pathol Int.
63:532–538. 2013.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Grillo F, Albertelli M, Brisigotti MP,
Borra T, Boschetti M, Fiocca R, Ferone D and Mastracci L: Grade
increases in gastroenteropancreatic neuroendocrine tumor metastases
compared to the primary tumor. Neuroendocrinology. 103:452–459.
2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Shi C, Gonzalez RS, Zhao Z, Koyama T,
Cornish TC, Hande KR, Walker R, Sandler M, Berlin J and Liu EH:
Liver metastases of small intestine neuroendocrine tumors: Ki-67
heterogeneity and World health organization grade discordance with
primary tumors. Am J Clin Pathol. 143:398–404. 2015.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Cives M and Strosberg JR:
Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin.
68:471–487. 2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Singh S, Hallet J, Rowsell C and Law CH:
Variability of Ki67 labeling index in multiple neuroendocrine
tumors specimens over the course of the disease. Eur J Surg Oncol.
40:1517–1522. 2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Keck KJ, Choi A, Maxwell JE, Li G,
O'Dorisio TM, Breheny P, Bellizzi AM and Howe JR: Increased grade
in neuroendocrine tumor metastases negatively impacts survival. Ann
Surg Oncol. 24:2206–2212. 2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Sorbye H, Welin S, Langer SW, Vestermark
LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K,
et al: Predictive and prognostic factors for treatment and survival
in 305 patients with advanced gastrointestinal neuroendocrine
carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 24:152–160.
2013.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Welin S, Sorbye H, Sebjornsen S, Knappskog
S, Busch C and Öberg K: Clinical effect of temozolomide-based
chemotherapy in poorly differentiated endocrine carcinoma after
progression on first-line chemotherapy. Cancer. 117:4617–4622.
2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Jiang R, Hong X, Zhao Y and Wu W:
Application of multiomics sequencing and advances in the molecular
mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett.
499:39–48. 2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
van Riet J, van de Werken HJG, Cuppen E,
Eskens FALM, Tesselaar M, van Veenendaal LM, Klümpen HJ, Dercksen
MW, Valk GD, Lolkema MP, et al: The genomic landscape of 85
advanced neuroendocrine neoplasms reveals subtype-heterogeneity and
potential therapeutic targets. Nat Commun. 12(4612)2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Scarpa A, Chang DK, Nones K, Corbo V,
Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et
al: Whole-genome landscape of pancreatic neuroendocrine tumours.
Nature. 543:65–71. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Mafficini A and Scarpa A: Genomic
landscape of pancreatic neuroendocrine tumours: The International
cancer genome consortium. J Endocrinol. 236:R161–R167.
2018.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Scarpa A: The landscape of molecular
alterations in pancreatic and small intestinal neuroendocrine
tumours. Ann Endocrinol (Paris). 80:153–158. 2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Pea A, Yu J, Marchionni L, Noe M, Luchini
C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, et al:
Genetic analysis of small well-differentiated pancreatic
neuroendocrine tumors identifies subgroups with differing risks of
liver metastases. Ann Surg. 271:566–573. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Cejas P, Drier Y, Dreijerink KMA, Brosens
LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK,
Valk GD, et al: Enhancer signatures stratify and predict outcomes
of non-functional pancreatic neuroendocrine tumors. Nat Med.
25:1260–1265. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Marinoni I: Prognostic value of DAXX/ATRX
loss of expression and ALT activation in PanNETs: Is it time for
clinical implementation? Gut gutjnl-2021-324664, 2021 (Epub ahead
of print).
|
|
88
|
Lewis PW, Elsaesser SJ, Noh KM, Stadler SC
and Allis CD: Daxx is an H3.3-specific histone chaperone and
cooperates with ATRX in replication-independent chromatin assembly
at telomeres. Proc Natl Acad Sci USA. 107:14075–14080.
2010.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Clynes D, Jelinska C, Xella B, Ayyub H,
Scott C, Mitson M, Taylor S, Higgs DR and Gibbons RJ: Suppression
of the alternative lengthening of telomere pathway by the chromatin
remodelling factor ATRX. Nat Commun. 6(7538)2015.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Singhi AD, Liu TC, Roncaioli JL, Cao D,
Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, et al:
Alternative lengthening of telomeres and loss of DAXX/ATRX
expression predicts metastatic disease and poor survival in
patients with pancreatic neuroendocrine tumors. Clin Cancer Res.
23:600–609. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Pavel M, Öberg K, Falconi M, Krenning EP,
Sundin A, Perren A and Berruti A: ESMO Guidelines Committee.
Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 31:844–860. 2020.PubMed/NCBI View Article : Google Scholar
|
|
92
|
VandenBussche CJ, Allison DB, Graham MK,
Charu V, Lennon AM, Wolfgang CL, Hruban RH and Heaphy CM:
Alternative lengthening of telomeres and ATRX/DAXX loss can be
reliably detected in FNAs of pancreatic neuroendocrine tumors.
Cancer Cytopathol. 125:544–551. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Heaphy CM, de Wilde RF, Jiao Y, Klein AP,
Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S,
et al: Altered telomeres in tumors with ATRX and DAXX mutations.
Science. 333(425)2011.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Luchini C, Lawlor RT, Bersani S, Vicentini
C, Paolino G, Mattiolo P, Pea A, Cingarlini S, Milella M and Scarpa
A: Alternative lengthening of telomeres (ALT) in pancreatic
neuroendocrine tumors: Ready for prime-time in clinical practice?
Curr Oncol Rep. 23(106)2021.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Dogeas E, Karagkounis G, Heaphy CM, Hirose
K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL and
Choti M: Alternative lengthening of telomeres predicts site of
origin in neuroendocrine tumor liver metastases. J Am Coll Surg.
218:628–635. 2014.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Hackeng WM, Brosens LAA, Kim JY,
O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J,
An S, et al: Non-functional pancreatic neuroendocrine tumours:
ATRX/DAXX and alternative lengthening of telomeres (ALT) are
prognostically independent from ARX/PDX1 expression and tumour
size. Gut gutjnl-2020-322595, 2021 (Epub ahead of print).
|
|
97
|
Kim JY, Brosnan-Cashman JA, An S, Kim SJ,
Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, et al:
Alternative lengthening of telomeres in primary pancreatic
neuroendocrine tumors is associated with aggressive clinical
behavior and poor survival. Clin Cancer Res. 23:1598–1606.
2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Marinoni I, Kurrer AS, Vassella E, Dettmer
M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ and Perren
A: Loss of DAXX and ATRX are associated with chromosome instability
and reduced survival of patients with pancreatic neuroendocrine
tumors. Gastroenterology. 146:453–460.e5. 2014.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Missiaglia E, Dalai I, Barbi S, Beghelli
S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A,
delle Fave G, et al: Pancreatic endocrine tumors: Expression
profiling evidences a role for AKT-mTOR pathway. J Clin Oncol.
28:245–255. 2010.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Stevenson M, Lines KE and Thakker RV:
Molecular genetic studies of pancreatic neuroendocrine tumors: New
therapeutic approaches. Endocrinol Metab Clin North Am. 47:525–548.
2018.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Zou Z, Tao T, Li H and Zhu X: mTOR
signaling pathway and mTOR inhibitors in cancer: Progress and
challenges. Cell Biosci. 10(31)2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Jiao Y, Shi C, Edil BH, de Wilde RF,
Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA,
et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently
altered in pancreatic neuroendocrine tumors. Science.
331:1199–1203. 2011.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Coriat R, Walter T, Terris B, Couvelard A
and Ruszniewski P: Gastroenteropancreatic well-differentiated grade
3 neuroendocrine tumors: Review and position statement. Oncologist.
21:1191–1199. 2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Hijioka S, Hosoda W, Matsuo K, Ueno M,
Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S,
et al: Rb loss and KRAS mutation are predictors of the response to
platinum-based chemotherapy in pancreatic neuroendocrine neoplasm
with grade 3: A Japanese multicenter pancreatic NEN-G3 study. Clin
Cancer Res. 23:4625–4632. 2017.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Ali AS, Grönberg M, Federspiel B, Scoazec
JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S,
Vestermark LW, et al: Expression of p53 protein in high-grade
gastroenteropancreatic neuroendocrine carcinoma. PLoS One.
12(e0187667)2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Basturk O, Tang L, Hruban RH, Adsay V,
Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL,
et al: Poorly differentiated neuroendocrine carcinomas of the
pancreas: A clinicopathologic analysis of 44 cases. Am J Surg
Pathol. 38:437–447. 2014.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Scoazec JY: Lung and digestive
neuroendocrine neoplasms. From WHO classification to biomarker
screening: Which perspectives? Ann Endocrinol (Paris). 80:163–165.
2019.PubMed/NCBI View Article : Google Scholar
|
|
108
|
George J, Lim JS, Jang SJ, Cun Y, Ozretić
L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, et al:
Comprehensive genomic profiles of small cell lung cancer. Nature.
524:47–53. 2015.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Derks JL, Leblay N, Thunnissen E, van
Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den
Broek EC, Chabrier A, et al: Molecular subtypes of pulmonary
large-cell neuroendocrine carcinoma predict chemotherapy treatment
outcome. Clin Cancer Res. 24:33–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Vijayvergia N, Boland PM, Handorf E,
Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ
and Engstrom PF: Molecular profiling of neuroendocrine malignancies
to identify prognostic and therapeutic markers: A fox chase cancer
center pilot study. Br J Cancer. 115:564–570. 2016.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Chen C, Notkins AL and Lan MS:
Insulinoma-associated-1: From neuroendocrine tumor marker to cancer
therapeutics. Mol Cancer Res. 17:1597–1604. 2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Tanigawa M, Nakayama M, Taira T, Hattori
S, Mihara Y, Kondo R, Kusano H, Nakamura K, Abe Y, Ishida Y, et al:
Insulinoma-associated protein 1 (INSM1) is a useful marker for
pancreatic neuroendocrine tumor. Med Mol Morphol. 51:32–40.
2018.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Fujino K, Motooka Y, Hassan WA, Ali
Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi
H, Kubota I, et al: Insulinoma-associated protein 1 is a crucial
regulator of neuroendocrine differentiation in lung cancer. Am J
Pathol. 185:3164–3177. 2015.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Augustyn A, Borromeo M, Wang T, Fujimoto
J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, et al:
ASCL1 is a lineage oncogene providing therapeutic targets for
high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA.
111:14788–14793. 2014.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Wang H, Chen Y, Fernandez-Del Castillo C,
Yilmaz O and Deshpande V: Heterogeneity in signaling pathways of
gastroenteropancreatic neuroendocrine tumors: A critical look at
notch signaling pathway. Mod Pathol. 26:139–147. 2013.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Rodriguez EF, Fite JJ, Chowsilpa S and
Maleki Z: Insulinoma-associated protein 1 immunostaining on
cytology specimens: An institutional experience. Hum Pathol.
85:128–135. 2019.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Modlin IM, Drozdov I and Kidd M: The
identification of gut neuroendocrine tumor disease by multiple
synchronous transcript analysis in blood. PLoS One.
8(63364)2013.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Kidd M, Drozdov I and Modlin I: Blood and
tissue neuroendocrine tumor gene cluster analysis correlate, define
hallmarks and predict disease status. Endocr Relat Cancer.
22:561–575. 2015.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Genzen JR, Mohlman JS, Lynch JL, Squires
MW and Weiss RL: Laboratory-developed tests: A legislative and
regulatory review. Clin Chem. 63:1575–1584. 2017.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Modlin IM, Aslanian H, Bodei L, Drozdov I
and Kidd M: A PCR blood test outperforms chromogranin A in
carcinoid detection and is unaffected by proton pump inhibitors.
Endocr Connect. 3:215–223. 2014.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Liu E, Paulson S, Gulati A, Freudman J,
Grosh W, Kafer S, Wickremesinghe PC, Salem RR and Bodei L:
Assessment of NETest clinical utility in a U.S. registry-based
study. Oncologist. 24:783–790. 2019.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Malczewska A, Bodei L, Kidd M and Modlin
IM: Blood mRNA measurement (NETest) for Neuroendocrine tumor
diagnosis of image-negative liver metastatic disease. J Clin
Endocrinol Metab. 104:867–872. 2019.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Modlin IM, Kidd M, Malczewska A, Drozdov
I, Bodei L, Matar S and Chung KM: The NETest: The clinical utility
of multigene blood analysis in the diagnosis and management of
neuroendocrine tumors. Endocrinol Metab Clin North Am. 47:485–504.
2018.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Öberg K, Califano A, Strosberg JR, Ma S,
Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling
A and Paulson S: A meta-analysis of the accuracy of a
neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann
Oncol. 31:202–212. 2020.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Hackeng WM, Morsink FHM, Moons LMG, Heaphy
CM, Offerhaus GJA, Dreijerink KMA and Brosens LAA: Assessment of
ARX expression, a novel biomarker for metastatic risk in pancreatic
neuroendocrine tumors, in endoscopic ultrasound fine-needle
aspiration. Diagn Cytopathol. 48:308–315. 2020.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Keutgen XM, Schadde E, Pommier RF,
Halfdanarson TR, Howe JR and Kebebew E: Metastatic neuroendocrine
tumors of the gastrointestinal tract and pancreas: A surgeon's plea
to centering attention on the liver. Semin Oncol. 45:232–235.
2018.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Demes M, Aszyk C, Bartsch H, Schirren J
and Fisseler-Eckhoff A: Differential miRNA-Expression as an
adjunctive diagnostic tool in neuroendocrine tumors of the lung.
Cancers (Basel). 8(38)2016.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Condrat CE, Thompson DC, Barbu MG, Bugnar
OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM and Voinea SC: MiRNAs
as biomarkers in disease: Latest findings regarding their role in
diagnosis and prognosis. Cells. 9(276)2020.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Roldo C, Missiaglia E, Hagan JP, Falconi
M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A and
Croce CM: MicroRNA expression abnormalities in pancreatic endocrine
and acinar tumors are associated with distinctive pathologic
features and clinical behavior. J Clin Oncol. 24:4677–4684.
2006.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Vicentini C, Fassan M, D'Angelo E, Corbo
V, Silvestris N, Nuovo GJ and Scarpa A: Clinical application of
microRNA testing in neuroendocrine tumors of the gastrointestinal
tract. Molecules. 19:2458–2468. 2014.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Panarelli N, Tyryshkin K, Wong JJM,
Majewski A, Yang X, Scognamiglio T, Kim MK, Bogardus K, Tuschl T,
Chen YT and Renwick N: Evaluating gastroenteropancreatic
neuroendocrine tumors through microRNA sequencing. Endocr Relat
Cancer. 26:47–57. 2019.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Kulke MH, Anthony LB, Bushnell DL, de
Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier
RF, Yao JC, et al: NANETS treatment guidelines: Well-differentiated
neuroendocrine tumors of the stomach and pancreas. Pancreas.
39:735–752. 2010.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15(38)2015.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Cives M, Simone V, Rizzo FM and Silvestris
F: NETs: organ-related epigenetic derangements and potential
clinical applications. Oncotarget. 7:57414–57429. 2016.PubMed/NCBI View Article : Google Scholar
|
|
135
|
House MG, Herman JG, Guo MZ, Hooker CM,
Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A and Yeo
CJ: Aberrant hypermethylation tumor suppressor genes in pancreatic
endocrine neoplasms. Ann Surg. 238:423–431; discussion 431-2.
2003.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Campana D, Walter T, Pusceddu S, Gelsomino
F, Graillot E, Prinzi N, Spallanzani A, Fiorentino M, Barritault M,
Dall'Olio F, et al: Correlation between MGMT promoter methylation
and response to temozolomide-based therapy in neuroendocrine
neoplasms: An observational retrospective multicenter study.
Endocrine. 60:490–498. 2018.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Walter T, van Brakel B, Vercherat C,
Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C,
Joly MO and Scoazec JY: O6-Methylguanine-DNA methyltransferase
status in neuroendocrine tumours: Prognostic relevance and
association with response to alkylating agents. Br J Cancer.
112:523–531. 2015.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Marzese DM, Hirose H and Hoon DS:
Diagnostic and prognostic value of circulating tumor-related DNA in
cancer patients. Expert Rev Mol Diagn. 13:827–844. 2013.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Boons G, Vandamme T, Peeters M, Beyens M,
Driessen A, Janssens K, Zwaenepoel K, Roeyen G, Van Camp G and Op
de Beeck K: Cell-free DNA from metastatic pancreatic neuroendocrine
tumor patients contains tumor-specific mutations and copy number
variations. Front Oncol. 8(467)2018.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Stroun M, Anker P, Maurice P, Lyautey J,
Lederrey C and Beljanski M: Neoplastic characteristics of the DNA
found in the plasma of cancer patients. Oncology. 46:318–322.
1989.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Raptis L and Menard HA: Quantitation and
characterization of plasma DNA in normals and patients with
systemic lupus erythematosus. J Clin Invest. 66:1391–1399.
1980.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Khan MS, Tsigani T, Rashid M, Rabouhans
JS, Yu D, Luong TV, Caplin M and Meyer T: Circulating tumor cells
and EpCAM expression in neuroendocrine tumors. Clin Cancer Res.
17:337–345. 2011.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Khan MS, Kirkwood A, Tsigani T,
Garcia-Hernandez J, Hartley JA, Caplin ME and Meyer T: Circulating
tumor cells as prognostic markers in neuroendocrine tumors. J Clin
Oncol. 31:365–372. 2013.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Khan MS, Kirkwood AA, Tsigani T, Lowe H,
Goldstein R, Hartley JA, Caplin ME and Meyer T: Early changes in
circulating tumor cells are associated with response and survival
following treatment of metastatic neuroendocrine neoplasms. Clin
Cancer Res. 22:79–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Childs A, Vesely C, Ensell L, Lowe H,
Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA and
Meyer T: Expression of somatostatin receptors 2 and 5 in
circulating tumour cells from patients with neuroendocrine tumours.
Br J Cancer. 115:1540–1547. 2016.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Krenning EP, Kwekkeboom DJ, Bakker WH,
Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M,
Reubi JC, et al: Somatostatin receptor scintigraphy with
[111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam
experience with more than 1000 patients. Eur J Nucl Med.
20:716–731. 1993.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Bombardieri E, Ambrosini V, Aktolun C,
Baum RP, Bishof-Delaloye A, Del Vecchio S, Maffioli L, Mortelmans
L, Oyen W, Pepe G, et al: 111In-pentetreotide scintigraphy:
Procedure guidelines for tumour imaging. Eur J Nucl Med Mol
Imaging. 37:1441–1448. 2010.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Hope TA, Bergsland EK, Bozkurt MF, Graham
M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, et
al: Appropriate use criteria for somatostatin receptor PET imaging
in neuroendocrine tumors. J Nucl Med. 59:66–74. 2018.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Eychenne R, Bouvry C, Bourgeois M, Loyer
P, Benoist E and Lepareur N: Overview of radiolabeled somatostatin
analogs for cancer imaging and therapy. Molecules.
25(4012)2020.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Ivanidze J, Roytman M, Sasson A, Skafida
M, Fahey TJ III, Osborne JR and Dutruel SP: Molecular imaging and
therapy of somatostatin receptor positive tumors. Clin Imaging.
56:146–154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Graham MM, Gu X, Ginader T, Breheny P and
Sunderland JJ: 68Ga-DOTATOC imaging of neuroendocrine tumors: A
systematic review and metaanalysis. J Nucl Med. 58:1452–1458.
2017.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Sadowski SM, Neychev V, Millo C, Shih J,
Nilubol N, Herscovitch P, Pacak K, Marx SJ and Kebebew E:
Prospective study of 68Ga-DOTATATE positron emission
tomography/computed tomography for detecting
gastro-entero-pancreatic neuroendocrine tumors and unknown primary
sites. J Clin Oncol. 34:588–597. 2016.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Deroose CM, Hindié E, Kebebew E, Goichot
B, Pacak K, Taïeb D and Imperiale A: Molecular imaging of
gastroenteropancreatic neuroendocrine tumors: Current status and
future directions. J Nucl Med. 57:1949–1956. 2016.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Miederer M, Seidl S, Buck A, Scheidhauer
K, Wester HJ, Schwaiger M and Perren A: Correlation of
immunohistopathological expression of somatostatin receptor 2 with
standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med
Mol Imaging. 36:48–52. 2009.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Kratochwil C, Stefanova M, Mavriopoulou E,
Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier
W, Haberkorn U and Giesel FL: SUV of [68Ga]DOTATOC-PET/CT Predicts
Response Probability of PRRT in neuroendocrine tumors. Mol Imaging
Biol. 17:313–318. 2015.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Strosberg J, El-Haddad G, Wolin E,
Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H,
et al: Phase 3 trial of (177)Lu-Dotatate for Midgut Neuroendocrine
tumors. N Engl J Med. 376:125–135. 2017.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Nicolas G, Mansi R, Vomstein S, Kaufmann
J, Bouterfa H, Maecke H, Wild D and Fani M: Wider safety window
with radiolabeled somatostatin receptor antagonists over agonists.
J Nucl Med. 56 (Suppl 3)(S335)2015.
|
|
161
|
Fani M, Nicolas GP and Wild D:
Somatostatin receptor antagonists for imaging and therapy. J Nucl
Med. 58 (Suppl 2):61S–66S. 2017.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Nock BA, Kaloudi A, Lymperis E, Giarika A,
Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T and
Baum RP: Theranostic perspectives in prostate cancer with the
Gastrin-Releasing peptide receptor antagonist NeoBOMB1: Preclinical
and first clinical results. J Nucl Med. 58:75–80. 2017.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Garin E, Le Jeune F, Devillers A, Cuggia
M, de Lajarte-Thirouard AS, Bouriel C, Boucher E and Raoul JL:
Predictive value of 18F-FDG PET and somatostatin receptor
scintigraphy in patients with metastatic endocrine tumors. J Nucl
Med. 50:858–864. 2009.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Ezziddin S, Adler L, Sabet A, Pöppel TD,
Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ and
Nagarajah J: Prognostic stratification of metastatic
gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET:
Feasibility of a metabolic grading system. J Nucl Med.
55:1260–1266. 2014.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Chan DL, Pavlakis N, Schembri GP, Bernard
EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, et
al: Dual somatostatin receptor/FDG PET/CT imaging in metastatic
neuroendocrine tumours: Proposal for a novel grading scheme with
prognostic significance. Theranostics. 7:1149–1158. 2017.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Hindié E: The netpet score: Combining FDG
and somatostatin receptor imaging for optimal management of
patients with metastatic well-differentiated neuroendocrine tumors.
Theranostics. 7:1159–1163. 2017.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Pavel M, O'Toole D, Costa F, Capdevila J,
Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et
al: ENETS consensus guidelines update for the management of distant
metastatic disease of intestinal, pancreatic, bronchial
neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
Neuroendocrinology. 103:172–185. 2016.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Panagiotidis E, Alshammari A, Michopoulou
S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M,
Belda M, Caplin ME, et al: Comparison of the impact of
68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients
with neuroendocrine tumors. J Nucl Med. 58:91–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Nilica B, Waitz D, Stevanovic V, Uprimny
C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B,
Virgolini I and Rodrigues M: Direct comparison of (68)Ga-DOTA-TOC
and (18)F-FDG PET/CT in the follow-up of patients with
neuroendocrine tumour treated with the first full peptide receptor
radionuclide therapy cycle. Eur J Nucl Med Mol Imaging.
43:1585–1592. 2016.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Ferté C, Fernandez M, Hollebecque A,
Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C,
Dromain C, et al: Tumor growth rate is an early indicator of
antitumor drug activity in phase I clinical trials. Clin Cancer
Res. 20:246–252. 2014.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Jain RK, Lee JJ, Ng C, Hong D, Gong J,
Naing A, Wheler J and Kurzrock R: Change in tumor size by RECIST
correlates linearly with overall survival in phase I oncology
studies. J Clin Oncol. 30:2684–2690. 2012.PubMed/NCBI View Article : Google Scholar
|
